Thrivent Financial for Lutherans Buys 2,688 Shares of DaVita Inc. (NYSE:DVA)

Thrivent Financial for Lutherans grew its stake in shares of DaVita Inc. (NYSE:DVA) by 49.4% during the third quarter, Holdings Channel reports. The institutional investor owned 8,131 shares of the company’s stock after buying an additional 2,688 shares during the period. Thrivent Financial for Lutherans’ holdings in DaVita were worth $1,333,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Mirae Asset Global Investments Co. Ltd. lifted its holdings in DaVita by 1.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock valued at $776,000 after purchasing an additional 70 shares in the last quarter. Wedmont Private Capital lifted its stake in shares of DaVita by 4.4% during the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after buying an additional 75 shares in the last quarter. Blue Trust Inc. boosted its holdings in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after buying an additional 78 shares during the period. First Trust Direct Indexing L.P. increased its stake in DaVita by 2.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock worth $500,000 after buying an additional 86 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in DaVita by 0.3% during the third quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock valued at $6,036,000 after acquiring an additional 126 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DVA. Bank of America increased their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Barclays increased their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. UBS Group boosted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, Truist Financial raised their target price on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $161.80.

DaVita Stock Performance

NYSE:DVA opened at $166.17 on Friday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a market cap of $13.63 billion, a price-to-earnings ratio of 17.93, a PEG ratio of 0.93 and a beta of 0.89. DaVita Inc. has a 1 year low of $99.18 and a 1 year high of $169.51. The stock’s 50 day simple moving average is $158.57 and its two-hundred day simple moving average is $149.31.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the prior year, the firm posted $2.85 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, equities analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Activity

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of DaVita stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the transaction, the chief executive officer now directly owns 887,835 shares of the company’s stock, valued at $144,583,929.75. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.